Investigation of In Vitro Susceptibility and Resistance Mechanisms in Skin Pathogens: Perspectives for Fluoroquinolone Therapy in Canine Pyoderma.
Stefano AzzaritiRoss BondAnette LoefflerFlavia ZendriDorina TimofteYu-Mei ChangLudovic PelligandPublished in: Antibiotics (Basel, Switzerland) (2022)
Fluoroquinolones (FQ) are commonly used in dogs with bacterial skin infections. Their use as first choice, along with the increased incidence of FQ-resistance, represents a risk to animal and public health. Our study determined minimum inhibitory (MIC) and bactericidal (MBC) concentrations of five FQs in Staphylococcus aureus , Staphylococcus pseudintermedius, and Escherichia coli, together with FQ-resistance mechanisms. MICs, efflux pump (EP) overexpression and MBCs were measured in 249 skin infection isolates following CLSI guidelines (CLSI VET01-A4, CLSI M26-A). Chromosomal and plasmid-mediated resistance genes were investigated after DNA extraction and sequencing. FQ-resistance was detected in 10% of methicillin-susceptible (MS), 90% of methicillin-resistant (MR) staphylococci and in 36% of E. coli . Bactericidal effect was observed except in 50% of MRSA/P for ciprofloxacin and in 20% of MRSPs for enrofloxacin. Highest MICs were associated with double mutation in gyrA (Ser83Leu + Asp87Asn), efflux pumps and three PMQR genes in E. coli , and grlA (Ser80Phe + Glu84Lys) in S. aureus . EP overexpression was high among E. coli (96%), low in S. aureus (1%) and absent in S. pseudintermedius . Pradofloxacin and moxifloxacin showed low MICs with bactericidal effect. Since in vitro FQ resistance was associated with MR, FQ use should be prudently guided by susceptibility testing.
Keyphrases
- staphylococcus aureus
- escherichia coli
- public health
- methicillin resistant staphylococcus aureus
- biofilm formation
- transcription factor
- soft tissue
- computed tomography
- magnetic resonance
- pseudomonas aeruginosa
- stem cells
- gene expression
- dna methylation
- mesenchymal stem cells
- cystic fibrosis
- wound healing
- multidrug resistant
- crispr cas
- antimicrobial resistance
- cell free
- circulating tumor
- copy number
- cell therapy
- global health